Last updated on September 2016

CHABLIS7.5: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis


Brief description of study

The purpose of this study is to evaluate the clinical efficacy of blisibimod as measured by a composite responder index in subjects who, despite corticosteroid use, continue to have seropositive, clinically-active Systemic Lupus Erythematosus (SLE) as defined by SELENA-SLEDAI score ≥10, and positive for anti-double stranded DNA and low complement (C3 or C4).

Clinical Study Identifier: NCT02514967

Contact Investigators or Research Sites near you

Start Over

Monica Gangal

Investigator Site 004
Tbilisi, Georgia
  Connect »

Monica Gangal

Investigator Site 001
Tbilisi, Georgia
  Connect »

Monica Gangal

Investigator Site 002
Tbilisi, Georgia
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.